

Italfarmaco S.p.A. study no: DSC/13/2984/05

Page 1 of 1

Table 14.2.4.2 Summary of Reduction of GH Level < 2.5 (mcg/litre) at the End of the Treatment Period  
(Intent-to-treat Analysis Set)

Period		Treatment			
		100 mcg Octreotide	500 mcg ITF2984	1000 mcg ITF2984	2000 mcg ITF2984
		(N=41) n (%)	(N=43) n (%)	(N=47) n (%)	(N=42) n (%)
1	Yes	0	0	2 ( 4.3)	6 ( 14.3)
	No	11 ( 26.8)	12 ( 27.9)	7 ( 14.9)	6 ( 14.3)
2	Yes	4 ( 9.8)	0	3 ( 6.4)	4 ( 9.5)
	No	8 ( 19.5)	8 ( 18.6)	9 ( 19.1)	7 ( 16.7)
3	Yes	2 ( 4.9)	2 ( 4.7)	2 ( 4.3)	4 ( 9.5)
	No	9 ( 22.0)	9 ( 20.9)	9 ( 19.1)	4 ( 9.5)
4	Yes	1 ( 2.4)	1 ( 2.3)	1 ( 2.1)	5 ( 11.9)
	No	6 ( 14.6)	10 ( 23.3)	10 ( 21.3)	6 ( 14.3)
Overall	Yes	7 ( 17.1)	3 ( 7.0)	8 ( 17.0)	19 ( 45.2)
	No	34 ( 82.9)	39 ( 90.7)	35 ( 74.5)	23 ( 54.8)

N = the number of subjects in the analysis set receiving the specified treatment.

n = the number of subjects with a measurement.

(%) = n/N\*100.

Source: Listing 16.2.6.1

PROGRAM NAME:T\_GHIGF\_02.SAS

DATE OF RUN:12SEP2016

TIME OF RUN: 11:55:24

DATE OF EXTRACTION:25MAY2016